157,353 Shares in Taysha Gene Therapies, Inc. $TSHA Acquired by Palumbo Wealth Management LLC

Palumbo Wealth Management LLC bought a new stake in Taysha Gene Therapies, Inc. (NASDAQ:TSHA) in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 157,353 shares of the company’s stock, valued at approximately $515,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. Vanguard Group Inc. raised its stake in Taysha Gene Therapies by 17.9% during the third quarter. Vanguard Group Inc. now owns 12,849,613 shares of the company’s stock worth $42,018,000 after purchasing an additional 1,955,486 shares during the period. Octagon Capital Advisors LP grew its stake in shares of Taysha Gene Therapies by 17.7% during the 2nd quarter. Octagon Capital Advisors LP now owns 12,592,500 shares of the company’s stock valued at $29,089,000 after buying an additional 1,892,500 shares during the period. Jefferies Financial Group Inc. increased its holdings in shares of Taysha Gene Therapies by 4,105.3% during the 2nd quarter. Jefferies Financial Group Inc. now owns 10,313,733 shares of the company’s stock worth $23,825,000 after buying an additional 10,068,479 shares during the last quarter. Adage Capital Partners GP L.L.C. purchased a new position in shares of Taysha Gene Therapies in the 2nd quarter worth $11,178,000. Finally, Tybourne Capital Management HK Ltd. raised its position in shares of Taysha Gene Therapies by 10.7% in the 2nd quarter. Tybourne Capital Management HK Ltd. now owns 4,095,000 shares of the company’s stock worth $9,459,000 after buying an additional 395,000 shares during the period. Institutional investors and hedge funds own 77.70% of the company’s stock.

Taysha Gene Therapies Price Performance

TSHA stock opened at $4.84 on Tuesday. The company has a debt-to-equity ratio of 0.23, a quick ratio of 10.48 and a current ratio of 10.48. Taysha Gene Therapies, Inc. has a 1 year low of $1.05 and a 1 year high of $6.02. The firm has a market cap of $1.33 billion, a P/E ratio of -14.67 and a beta of 1.01. The stock has a 50-day simple moving average of $5.00 and a 200-day simple moving average of $4.35.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on the company. The Goldman Sachs Group set a $11.00 price target on Taysha Gene Therapies in a research report on Thursday, December 4th. Wall Street Zen lowered Taysha Gene Therapies from a “hold” rating to a “sell” rating in a research note on Saturday, January 3rd. Raymond James Financial reiterated a “strong-buy” rating and set a $13.00 target price on shares of Taysha Gene Therapies in a report on Tuesday, January 6th. Cantor Fitzgerald restated an “overweight” rating and issued a $13.00 price target on shares of Taysha Gene Therapies in a report on Friday, November 14th. Finally, Citigroup reaffirmed an “outperform” rating on shares of Taysha Gene Therapies in a research report on Wednesday, November 5th. One research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $10.91.

Insiders Place Their Bets

In other Taysha Gene Therapies news, insider Sukumar Nagendran sold 260,047 shares of the stock in a transaction that occurred on Monday, December 1st. The shares were sold at an average price of $4.51, for a total value of $1,172,811.97. Following the completion of the sale, the insider owned 1,006,439 shares of the company’s stock, valued at $4,539,039.89. This trade represents a 20.53% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Kamran Alam sold 78,968 shares of Taysha Gene Therapies stock in a transaction that occurred on Friday, January 23rd. The shares were sold at an average price of $4.75, for a total transaction of $375,098.00. Following the sale, the chief financial officer owned 1,467,635 shares in the company, valued at $6,971,266.25. This represents a 5.11% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 968,795 shares of company stock worth $4,518,093 in the last 90 days. 3.78% of the stock is owned by company insiders.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc (NASDAQ: TSHA) is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders.

Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies completed its initial public offering in May 2021.